NewAmsterdam Pharma Co N.V.
For the period ended Mar 31, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 8, 2025
NAMS$19.18+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| For the three months ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| (In thousands of USD) | ||
| Operating activities: | ||
| Loss for the period | (39,527) | (93,767) |
| Non-cash adjustments to reconcile loss for the period to net cash flows: | ||
| Depreciation and amortization | 52 | 15 |
| Non-cash rent expense | 3 | 1 |
| Fair value change - derivative earnout and warrants | (17,754) | 38,950 |
| Foreign exchange (gains)/losses | (4,293) | 2,418 |
| Amortization of premium/discount on available-for-sale debt securities | (513) | — |
| Share-based compensation | 15,213 | 7,918 |
| Changes in working capital: | ||
| Changes in prepayments (current and non-current) and other receivables | 16,031 | 956 |
| Changes in accounts payable | 2,251 | (8,311) |
| Changes in accrued expenses and other current liabilities | (4,953) | (1,381) |
| Changes in deferred revenue | (2,978) | (1,401) |
| Net cash used in operating activities | (36,468) | (54,602) |
| Investing activities: | ||
| Purchase of property, plant and equipment, including internal use software | (16) | (385) |
| Maturity of available-for-sale debt securities | 12,500 | — |
| Purchase of available-for-sale debt securities | (9,629) | — |
| Net cash (used in)/provided by investing activities | 2,855 | (385) |
| Financing activities: | ||
| Proceeds from February 2024 offering of Ordinary Shares and Pre-Funded Warrants | — | 190,481 |
| Transaction costs on February 2024 issue of Ordinary Shares and Pre-Funded Warrants | — | (515) |
| Transaction costs on December 2024 issue of Ordinary Shares and Pre-Funded Warrants | (1,586) | — |
| Proceeds from exercise of warrants | 183 | 8,763 |
| Proceeds from exercise of options | 7,922 | 440 |
| Payment of withholding taxes related to net share settlement of exercised options | — | (989) |
| Net cash provided by financing activities | 6,519 | 198,180 |
| Net change in cash | (27,094) | 143,193 |
| Foreign exchange differences | 3,771 | (2,496) |
| Cash and cash equivalents at the beginning of the year | 771,743 | 340,450 |
| Cash and cash equivalents at the end of the year | 748,420 | 481,147 |
| Noncash financing and investing activities | ||
| Receivable related to exercise of warrants | — | 1,271 |
| Issuance of earnout shares | 40,807 | — |
See notes to consolidated financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.